References in periodicals archive ?
entity amphetamine) AGRYLIN (anagrelide hydrochloride) BUCCOLAM
On November 25, 2014 Shire launched AGRYLIN in Japan for treatment of adults with essential thrombocythemia, following approval of a marketing authorization on September 26, 2014 by the Ministry of Health, Labor and Welfare in Japan.
Shire Pharmaceuticals Group plc (Nasdaq: SHPGY; LSE: SHP; TSX: SHQ), Basingstoke, England, has been signed an agreement with a leading haematology specialty company, the Pharmaceutical Division of Kirin Brewery Company Ltd, granting the rights to develop, register, formulate, package, label, market and sell AGRYLIN (anagrelide hydrochloride) in Japan, the world's second largest pharmaceuticals market.
Sales of Shire's blood disorder treatment Agrylin rose 14 per cent in the quarter to pounds 19 million while its Reminyl drug achieved a 14.
In the first 6 months of 1997, the following new drugs were approved by the FDA: Agrylin, Alesse, Anzemet, Carbatrol, Fareston, Flomax, Galzin, Idamycin, Migranal, Posicor, Prelay, Prevacid, Pytest, Requip, Resulin, Serlect, Skelid, Tasmar, Uniretic, Urso, Vicoprofen, Viracept, Zyban.
Accupril - Agrylin - Axid - Biaxin - Celexa - Cipro - Difl ucan - Duragesic - Effexor - Flonase - Floxin/Occufl ox - Glucophage XR - Glucotrol XL - Glucovance - Lotensin - Metaglip - Mobic - Monopril - Novantrone - Paraplatin - Paxil - Pravachol - Proscar - Retrovir - Rocephin - Romazicon - Tambocor - Ultram - Zaditor - Zestril/Prinivil - Zithromax - Zocor - Zofran - Zoloft
We continue to build our international presence and our expansion into the Japanese market with the approval of VPRIV and AGRYLIN.
MHLW") in Japan, seeking approval for AGRYLIN in adult
AGRYLIN sales in North America (US and Canada) were US$7.
Shire Pharmaceuticals markets Agrylin for the treatment of thrombocytosis and essential thrombocythaemia.
following the approval of generic versions of AGRYLIN in the US market in April
This reduction was expected following the approval of generic versions of AGRYLIN in the US market in April 2005.